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Introduction 
Mesenchymal stem cells (MSCs) have been isolated from a broad 
range of tissues including bone marrow, peripheral blood, umbilical 
cord blood and the umbilical cord itself, adipose tissue, periosteum, 
deciduos teeth, amniotic fluid and membranes and fetal tissues 
[1,2]. Isolated MSCs from all these sources are able to differentiate 
towards cell types of the mesodermal lineage. The immune pheno-
type of MSCs, lacking expression of main histocompartibility com-
plex II and costimulatory molecules, are regarded as immunosup-
pressive [3]. All these characteristics make MSCs an indispensable 
source for cell replacement therapy of degenerative age-dependent 
or trauma-associated conditions [4]. Banking of MSCs provides an 
opportunity to have controlled MSC batches ready for transplanta-
tion. Umbilical cords represent a readily available source of MSCs 
which is usually discarded directly after birth. The umbilical cord 
contains MSCs with a higher proliferation capacity compared to 
bone marrow derived MSCs, especially when isolated from aged 
donors. 
DMSO is the most commonly used cryoprotectant because of its 
high-membrane permeability. Fetal bovine serum (FBS) is used in 
combination with DMSO in order to stabilise the cell membrane and 
to adjust osmotic pressure [5-8]. These two components are the 
most common cryoprotectants for MSCs, however, both have dis-
advantages. DMSO is known to cause various side-effects including 
neurological damage, gastrointestinal effects and mutations, among 
others [9-12]. Bovine serum is also undesirable as it carries the risk 
of transmitting viral diseases and it may initiate immune responses; 
however, the alternative use of autologus serum is time-consuming.  
The aim of our study was to find an alternative cryoprotection solu-
tion by replacing DMSO and serum in the cryopreservation solution 
while providing high viability and recovery rate of hMSCs. We 
choose hydroxyethyl starch (HES), sorbitol and dextran as alterna-
tive cryoprotectants as they are already approved for medical use. 
Former experiments of our group using only HES as a sole cryopro-
tectant for cryopreservation of rat MSCs were not successful in 
terms of achieving an acceptable level of cryopreservation efficacy 
[13]. We therefore sought to improve the proceduere by including 
additional substances. Sorbitol is an organic osmolyte which has 
shown protective functions for cryopreservation of red blood cells 
preventing hyper-and hypo-osmotic cell damage [14]. Polyalcohols 
have shown to provide successful cryoprotection for oocytes and 
embryos [15]. Some approved and commonly used polymers such 
as dextran have been already successfully recruited as alternative 
cryoprotectants for freezing different cell types [16,17]. We ana-
lysed the identity of the isolated MSCs and tested growth character-
istics and differentiation potential before and after cryopreservation 
with different combinations of the cryoprotectants.  
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replacing DMSO and FCS. We found that a cryosolution containing 5% HES, 0.3M sorbitol and 5% dextran provide successful protection for 
human umbilical cord derived mesenchymal stem cells. These MSC retain a high viability and show multilineage differentiation. 
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Material and Methods 
Isolation and Culture of Mesenchymal Stem Cells 
MSCs were isolated from umbilical cords (UCs). The material was 
collected from the Saint Elisabeth hospital using consent forms. 
UCs were stored in PBS and processed within 8h after delivery. 
UCs were washed with PBS and transferred to petri dishes, cut into 
sections of approximately 1cm in diameter. Sections from 1 UC 
were then transferred to 2-3 culture dishes and left without medium 
for 10-15 min to attach. After that time, 20ml medium (Dulbecco’s 
modified Eagle’s medium (DMEM, 1 g/L D-Glucose; Invitrogen) 
containing 10% fetal bovine serum (FBS; Hyclone) and 1% penicil-
lin/streptomycin (Invitrogen) was added to each culture dish. Medi-
um was changed every 2 days until outgrowth from the sections 
were visible. The sections were transferred to a new culture dish. 
Up to 3 transfers can be performed. Culture dishes with outgrowth 
were left for ~1 week until expansion of the cells was observed, this 
step was counted as passage 0. For the cryopreservation experi-
ment MSCs on passage 1 - 3 were used.  
Cryopreservation 
MSCs were frozen when they reached 80% confluence. Cell num-
ber was determined by trypan blue staining using a Neubauer he-
mocytometer. Final volume of cells with cryoprotectant was 500μl. 
Each cryovial contained 5x105 MSC. HES with molecular weight 
(MW) 200 and 450 kDa, sorbitol, mannitol and dextran with MW=5, 
450 and 500 kDA were obtained from Serumwerke Bernburg 
GmBH. All components were diluted in either ringer acetate solution 
(RAS), Gelafusal or DMEM. Cells were frozen using the pro-
grammed rate freezer (Thermo Scientific). Cooling started at 4°C 
with a cooling rate of 1°C/min until -30°C, then at a rate of 5°C/min 
until -80°C then the MSCs were transferred into the gas phase of 
the liquid nitrogen tank. Thawing was performed in the water bath, 
at 37°C. 
Viability Assessment 
After thawing, cells were stained with trypan blue and counted with 
a Neubauer chamber. Percent of viable cell cells was calculated as 
a ratio of live unstained cells to number of frozen cells (5x105). 
Phenotyping of Mesenchymal Stem Cells 
MSCs were stained for CD90 using Alexa488-conjugated AB at a 
1:10 dilution (Abcam), CD105 using Alexa647-conjugated AB 
(Serotec) at a 1:100 dilution, CD44 using AF488-conjugated AB 
(Abcam) at a 1:100 dilution, CD31 using Cy3-conjugated AB 
(Abcam) at a 1:50 dilution, CD45 using FITC-conjugated AB 
(Abcam) at 1:10 dilution and CD11b using FITC-conjugated AB 
(Abcam) at a 1:10 dilution, for 1 h at 4°C in the dark followed by 3-
time washing with PBS. Stained cells were analyzed using 
FACScalibur flow cytometer (BD). 
MTT Assay 
The MTT assay was performed 3 days after thawing. Each well was 
filled with 500µl of media containing the MTT-reagent, consisting of 
5mg/ml MTT (Carl Roth) in PBS. After incubation for 4h at 37°C, 
medium was removed and 500µl stop-solution (10% SDS (Merck) 
and 50% dimethylformamide, (VWR International)) was added. The 
cells were incubated overnight at 37°C and absorbance was meas-
ured using a microplate reader (TECAN) at 550nm and 630nm as 
reference wavelength. 
Osteogenic Differentiation 
The day after thawing, medium was changed to osteo-inductive 
medium (low Glucose DMEM; 10% FBS; 1% pen/strep; 10nm dexa-
methasone, (Sigma-Aldrich); 50µg/ml ascorbic acid 2-phosphate, 
(Sigma-Aldrich). Differentiation media was changed every 2 days 
for a period of 14 days. For qualitative analysis of osteogenic differ-
entiation, cells were fixed in 70% ethanol for 15 min and washed 
once with ddH2O. After washing, cells were stained with ALP buffer 
pH 8.5 (0.2M Tris, 1mg/ml fast red, Sigma and 50µg/ml naphtol 
phosphate AS-BI, Sigma) for 1hr. 
Adipogenic Differentiation 
Adipogenic medium (10% FBS; 1% pen/strep, 10% insulin-
transferrin-selenium supplement, (Sigma-Aldrich) 10-8M dexame-
thasone (Sigma-Aldrich); 0.5mM isobutylmethylxanthin, Sigma-
Aldrich; 100µM indomethacin, Sigma-Aldrich) was added the day 
after thawing. The media was changed every 2 days. After 14 days 
cell phenotype was analyzed by Oil Red O (Sigma-Aldrich) staining.  
Chondrogenic Differentiation 
Chondrogenic media (10% FBS; 1% pen/strep 1% insulin-
transferrin-selenium supplement (Sigma-Aldrich), 10-7M dexame-
thasone (Sigma-Aldrich), 150µM ascorbic-2-phosphate (Sigma-
Aldrich), 20µM linoic acid (Sigma-Aldrich) and 0.1ng/ml TGF-β 
(Oncogenic Sciences) was added the day after thawing. After 2 
weeks, cells were stained with Alcian Blue (Sigma-Aldrich). 
Cell Morphology 
Morphology of the cells was analyzed 3 days after thawing under a 
light microscope. Pictures were taken at 10x magnification with the 
Leica system. 
Statistics 
All experiments were repeated at least three times with three differ-
ent donors. Statistical analysis was performed using ANOVA fol-
lowed by Tukey test, with p < 0.05 considered statistically significant 
using Sigma Plot. 
Results 
The MSCs derived from the umbilical tissue showed fibroblast-like 
morphology [Fig-1B] and were positive for the surface markers 
CD44, CD90, CD105 and negative for CD11b, CD31, and CD45 
[Fig-1A]. Following cultivation in osteo-inductive, chondro-inductive 
and adipo-inductive medium, cells differentiate into osteoblasts, 
chondrocytes and adipocytes, respectively proving that they are 
truly mesenchymal stem cells [Fig-1C], [Fig-1D] and [Fig-1E]. 
MSCs were frozen with different solutions to identify the best cryo-
solution. Cell viability was measured on day 0 and day 3. A higher 
significant cell viability was found with the solutions containing 0.3M 
sorbitol / 10% dextran in DMEM and 10% DMSO in serum (p ≤ 
0.039) compared to 0.3M sorbitol in DMEM [Fig-2A]. The other 
solutions tested show no significant differences in cell viability. 
However significant cell loss is observed on day 3 after thawing for 
nearly all cryosolutions, showing that cell death occurs during the 
24h after thawing. In all later experiments we only used day 3 data 
[Fig-2B]. 
The solution that (without DMSO) provided the highest viability con-
tained 5% HES200, 0.3M sorbitol and 10% dextran5 compared to 
10% DMSO in DMEM [Fig-2B]. Significances in cell viability at day 
3 were determined for 10% DMSO in serum (+p ≤ 0.001) compared 
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to solutions containing, DMSO, sorbitol, dextran, mannitol and/or 
HES in DMEM. The cryosolution of 10% DMSO in DMEM showed 
significant (∞p ≤ 0.033) increase in cell viability when compared to 
5% DMSO/mannitol,sorbitol, sorbitol/dextran5 and HES/sorbitol/5% 
dextran5. In addition, 10% DMSO/10% dextran5, 5% DMSO/5% 
HES and 5% HES/sorbitol/5% dextran5 showed statistically signifi-
cant increase in cell viability (§p ≤ 0.014) compared to sorbitol and 
sorbitol/10% dextran 5. Differences were observed between the use 
of 5 and 10% dextran5 with HES and sorbitol. Dextran5 at 5% con-
centration (p = 0.02) showed a decrease in cell viability compared 
to 10% dextran5.  
Fig. 1- MSC phenotyping. Characterization of freshly isolated MSCs 
from human umbillical cord. CD-phenotyping (A), Morphology of 
freshly isolated cells, 10X (B) ALP-activity staining in MSCs after 
osteogenic differentiation, 20X(C), oil red staining of differentiated 
MSC towards adipocyte lineage, 40X(D) and alcian blue staining 
after chondrogenic differentiation 20X (E). 
Fig. 2- Viability of cryopreserved hMSCs in comparison to fresh 
cells. Viability of cryopreserved MSC directly after thawing on day 0 
by trypan blue (A). Determination of viability of hMSCs at day 3 
after thawing using MTT-test (B). The following cryoprotectans were 
used: HES with MW= 200kDa, dextran with MW=5 kDa, in DMEM. * 
- means statistically significances in comparison to fresh cells. 
In the next experiments we tested a smaller dextran (dextran5) 
versus dextran450 at two different concentrations [Fig-3A] while 
keeping the beneficial sorbitol and HES200. We found that 10% 
dextran450 in ring acetate and 5-10% DMSO in ring acetate were 
significantly better (*p < 0.01) compared to dextran5 and 5% dex-
tran450 [Fig-3A]. Usage of 5% dextran450 in gelafusal and 5-10% 
DMSO in serum showed a statistical increase (∞p ≤ 0.038) in cell 
viability compared to 10% dextran5. In addition, higher cell viability 
was observed for 10% DMSO in gelafusal (+p ≤ 0.001) compared 
to dextran5 and 10% dextran450 in gelafusal. Cell viability of cryo-
preserved cells in the different solutions were compared to fresh 
cells and we found lower cell viability for solutions containing dex-
tran5 (§p ≤ 0.012). Similar results in cell viability were obtained for 
5% DMSO in ring acetate (§p ≤ 0.001) compared to dextran5.  
In a further attempt to increase cell viability, we tested if a lower 
sorbitol concentration, 0.15M, is as effective as 0.3M sorbitol [Fig-
3B] and found no significant difference. We therefore used 0.3M 
sorbitol in subsequent experiments. Comparison of solutions contai-
nig sorbitol, HES and dextran showed significant decrease in cell 
viability compared to DMSO in ring acetate [Fig-3B]. In addition, we 
tested different HES/dextran combinations with different osmolarity 
and found no difference either, there was however a trend that the 
HES 200/dextran450 solution was leading to better cell viability [Fig
-3B]. Therefore, dextran450 was chosen for further improvements 
with the goal to replace the medium containing serum and switch to 
a fully defined buffer system. 
Fig. 3- Cryopreservation of hMSCs in DMSO- and FCS free- cryo-
solution. Viability of hMSCs at day 3 after cryopreservation in solu-
tion containing HES, sorbitol/mannitol and dextran with MW=5 and 
450 kDa in Ringer Acetate, Gelafusal or DMEM (A). Viability at day 
3 of hMSCs after cryopreservation in solutions containing HES200 
and dextran450 or HES450 and dextran500 prepared in Ringer 
acetate solution (B). Effect of sorbitol in comparison to mannitol, in 
combination with HES200 and dextran450 (C). 
For the next step, we compared a mixture containing HES200 and 
0.3M sorbitol concentration with an alternative to sorbitol, mannitol, 
in two different buffer systems: ringer acetate and gelafusal [Fig-
3C]. Solutions containing sorbitol in gelafusal showed higher cell 
viability (p = 0.011) compared to mannitol in ring acetate. Differ-
ences in cell viability were determined for mannitol in gelafusal 
compared to ring acetate. A significant decrease in cell viability was 
determined for mannitol in ring acetate (p = 0.05) compared to gela-
fusal.  
The MSC morphology was not affected in the serum free cryosolu-
tions containing HES200, sorbitol and dextran450 in ring acetate 
[Fig-4]. In addition we differentiated the MSCs with the HES/sorbitol 
and dextran solution after cryopreservation and found that the dif-
ferentiation capacity was preserved [Fig-5]. 
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Fig. 4- Morphology of fresh and cryopreserved human MSC. Fresh 
MSCs at passage 3 (A) and MSCs after cryopreservation using the 
conventional solution with 10%DMSO and 90%FCS (B). Morpholo-
gy of cryopreserved MSCs with cryopreservation with 5%DMSO 
and 90%FCS (C), 10%DMSO and 90% Ringer Acetate solution (D), 
5%DMSO and 90%Ringer Acetate solution (E) and 5%
HES450+0.3M Sorbitol+ 5%Dextran 500 (F). 
Fig. 5- Determination of differentiation capacity of cryopreserved 
MSC. Fresh and cryopreserved MSC in the different solutions were 
differentiated for 14 days into osteoblast, adipocytes and chondro-
cytes.  
Discussion  
MSCs are very promising for clinical therapy because of their ac-
cessibility, multilineage potentials and immune-suppression activi-
ties [18,19]. The placenta and umbilical cord are attractive sources 
of MSCs. Placentas are discarded at birth, providing an ample tis-
sue source, and in our experience, represent a relatively large res-
ervoir of MSCs, minimising the expansion required to obtain the 
required numbers of cells for research and possibly clinical applica-
tions. Placental MSCs show classical MSC surface phenotype, 
differentiation potential and potent immunosuppressive properties 
[20,21].  
Many reasons exist to cryopreserve stem cells: multiple cell trans-
plantations, allogeneic applications and gene therapy approaches 
using stem cells. There is a growing concern about the affect of 
DMSO and serum in the process of human cell cryopreservation, 
banking and consequent use of cryopreserved cells in transplanta-
tion [22]. Possible complications after transplantation of DMSO-
cryopreserved cells represent a serious cause for substitution of 
these cryoprotectants with less harmful and dangerous compo-
nents. The present study focuses on the possibility of replacing 
serum and DMSO in cryopreservation medium for human MSCs.  
The solution tested here contains HES, sorbitol and dextran which 
have been used by other researchers to increase cell cryopreserva-
tion efficiency and to reduce the concentration of DMSO in cryoso-
lutions, but in all those experiments these components have always 
been used together with additional cryopotective agents – usually 
DMSO, serum or albumin [23-25]. In our study we have shown that 
neither HES, nor sorbitol or dextran are able to provide efficient 
cryoprotection when used alone as a single cryoprotectant in serum
-free solution even in presence of DMSO [Fig-2B] 
We combined these three components, HES, sorbitol and dextran, 
in order to achieve high cell viability and recovery rates of human 
MSCs after thawing [Fig-3A], [Fig-3B]. The mechanism by which 
HES, sorbitol and dextran positively affect cryopreservation efficacy 
are not clearly understood. HES and dextran both serve as organic 
osmolytes preventing hyper- and hypo-osmotic cell damage and 
intracellular ice formation upon the cooling process [26]. Large mol-
ecules like HES and dextran increase the viscosity of the solution 
and decrease the cooling rate required for optimal survival during 
vitrification, while simultaneously increase the tendency of super-
cooling and kinetically inhibit ice formation [27,28]. 
There is no consensus in the literature about the extent of sorbitol 
permeability through mammalian cell membranes. According to 
Alvarez and Storey, sorbitol penetrates the cellular membrane and 
is therefore considered to be an intracellular cryoprotectant [29]. 
Other scientists consider the sorbitol molecule to be non-
penetrating for the majority of cells under normal conditions [30]. 
Kracke et al. concluded that there is a specific sorbitol transport 
pathway, at least in human erythrocytes, similar to the sorbitol per-
mease in renal epithelial cells [31]. As the organic osmolyte, sorbitol 
prevents osmotic damage in red blood cells [14] and early mamma-
lial embryos [15]. Here we show that sorbitol and mannitol, both 
being polyols, act in a similar way when utilized in a cryoprotective 
solution. There is a non-significant tendency towards higher values 
of cell viability for sorbitol compared to to mannitol. We compared 
the efficacy of solutions for cryopreservation of MSCs containing 
HES 200 and Dextran 450 to those containing HES 450 and Dex-
tran 500. The cryopreservation efficiency for MSCs was unaffected 
by the molecular weight of polymeric HES and Dextran. This obser-
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vation may be due to the fact that all compounds tested belong to 
the high molecular weight polymers and differences in molecular 
weight do not contribute significantly to their physical properties. 
Differences in the concentration of HES and dextran, 5 and 10%, 
similar to the average weight of the polymers, do not have a statisti-
cally significant affect on cell viability on day 3. 
In the present study we have demonstrated that both DMSO and 
serum can be replaced using a combination of substances which 
provide good cell viability after cryopreservation. Human MSCs 
after cryopreservation using a combination of HES, sorbitol and 
dextran retain their characteristics and ability to differentiate to-
wards adipogenic, osteogenic and chondrogenic lineages. 
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